List view / Grid view
18 July 2014 | By Amgen
Amgen announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease...
18 July 2014 | By GlaxoSmithKline
...phase III BRAF V600-mutant metastatic melanoma study stopped early.
18 July 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion...
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
17 July 2014 | By Teva
Teva Pharmaceutical Industries Ltd. reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director...
17 July 2014 | By Pfizer
Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B...
17 July 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that for the first time the U.S. Food & Drug Administration has granted Breakthrough Therapy designation for a treatment in idiopathic pulmonary fibrosis...
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
16 July 2014 | By Biogen Idec
Biogen Idec announced a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis across the country...
15 July 2014 | By kdm communications
Tecan has extended the flexibility of its popular Cavro® Omni Robot with the introduction of embedded control functions and the option to select single axis configurations...
15 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets...
15 July 2014 | By Novartis
Novartis announced a collaboration with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention...
15 July 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer...
14 July 2014 | By Teva
First breath-actuated dry-powder SABA inhaler to be accepted by FDA for review...
14 July 2014 | By Abbott
Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company...
